- PR Newswire•6 months ago
PharmaEngine Announces Onivyde(R) Receives European Marketing Authorization for the Treatment of Metastatic Adenocarcinoma of the Pancreas Following Gemcitabine based Therapy
TAIPEI, Taiwan, Oct. 18, 2016 /PRNewswire/ -- PharmaEngine, Inc. (TWO: 4162) announced that the European Commission (EC) has granted Shire plc (PharmaEngine's sublicensee, LSE: SHP, NASDAQ: SHPG) a marketing ...
- PR Newswire•9 months ago
PharmaEngine Announces ONIVYDE(R) Regimen Receives CHMP Positive Opinion for the Treatment of Metastatic Pancreatic Cancer
TAIPEI, Taiwan, July 25, 2016 /PRNewswire/ -- PharmaEngine, Inc. (TWO:4162) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a marketing authorization of ONIVYDE® (irinotecan liposome injection, nal-IRI) in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for the treatment of metastatic adenocarcinoma of the pancreas in adult patients who have progressed following gemcitabine based therapy. The CHMP positive opinion for ONIVYDE will now be reviewed by the European Commission for marketing authorization in the European Union (EU).
- PR Newswire•11 months ago
PharmaEngine Announces Initiation of Global Pivotal Trial of PEP503 (NBTXR3) in Soft Tissue Sarcoma in Asia Pacific Region
TAIPEI, Taiwan, May 31, 2016 /PRNewswire/ -- PharmaEngine Inc. (TWO:4162) announced today that the first patient has been dosed in a global pivotal phase II/III trial of PEP503 (NBTXR3) in soft tissue sarcoma (STS) at Perpetual Succour Hospital, Cebu, Philippines. This multi-national, randomized, open-label, two-arm pivotal phase II/III trial, referred to as Study 301 (Act.in.sarc study), is being conducted in partnership with PharmaEngine's partner, Nanobiotix S.A. (Euronext:NANO). PharmaEngine is the co-sponsor of this Study 301 in the Asia-Pacific Region.
4162.TWO: Summary for PHARMAENGINE INC TWD10 - Yahoo Finance
PHARMAENGINE INC TWD10 (4162.TWO)
Taiwan OTC - Taiwan OTC Delayed price. Currency in TWD
Add to watchlist
|Day's range||185.00 - 187.50|
|52-week range||171.68 - 255.00|
|PE ratio (TTM)||N/A|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|